RxSight, Inc. reiterating earnings guidance for the full year 2024, for the year, the company expects revenue guidance range of $128.0 million to $135.0 million, representing implied growth of 44% to 52% compared to 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.29 USD | +6.78% | +5.98% | +59.45% |
05-13 | RxSight Raises $115 Million From Public Offering of Shares | MT |
05-07 | Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.45% | 2.35B | |
-4.98% | 181B | |
+2.84% | 112B | |
-2.68% | 67.92B | |
+4.53% | 50.1B | |
+8.00% | 44.27B | |
+10.41% | 40.41B | |
+25.30% | 31.95B | |
-0.17% | 25.82B | |
+20.25% | 25.29B |
- Stock Market
- Equities
- RXST Stock
- News RxSight, Inc.
- Rxsight, Inc. Reiterates Earnings Guidance for the Full Year 2024